NexEos Bio was founded with a mission of developing novel technologies to identify and treat eosinophil and cationic protein-mediated inflammation.

We bring a sense of urgency to all we do, knowing patients need better solutions to manage their debilitating diseases.

Illuminating eosinophil-driven inflammation for a brighter tomorrow.

We are passionate about our goal of helping patients to maintain a high quality of life and to slow the progression of eosinophil-related diseases.

About Us

Our lead therapeutic program, NTX-1024, is a topical ophthalmic solution designed to target and inhibit cationic granule proteins in eosinophil-driven ocular disease including VKC and other forms of allergic conjunctivitis.

NTX-1024

Our lead diagnostic program, NDX-3324, is a novel, non-invasive imaging agent for the detection, diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE).

NDX-3324

NexEos Bio was founded with a mission of developing novel technologies to identify and treat eosinophil and cationic protein-mediated inflammation. We bring a sense of urgency to all we do, knowing patients need better solutions to manage their debilitating diseases.

Illuminating eosinophil-driven inflammation for a brighter tomorrow.

NexEos Bio was founded with a mission of developing novel technologies to identify and treat eosinophil and cationic protein-mediated inflammation.

We bring a sense of urgency to all we do, knowing patients need better solutions to manage their debilitating diseases.